Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.

In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse.

Key topics covered in this episode:
● AQUILA update: Daratumumab in high-risk smoldering myeloma, and the ongoing clinical dilemma
● COBRA: Is KRD superior to VRD in newly diagnosed multiple myeloma? Unpacking the MRD and PFS data.
● TecLILLE: A first look at Teclistamab + Daratumumab in frontline, transplant-ineligible patients.
● MajesTEC-3: PFS and OS data for Teclistamab + Daratumumab in first relapse, and its impending FDA approval.

Tune in for this expert breakdown to navigate the new myeloma landscape with confidence.

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Subscribe for more deep dives into treatment algorithms and major conference highlights!

#OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART

ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose